¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"low affinity platelet factor IV"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • platelet concentrate
    Ç÷¼ÒÆÇ³óÃ๰
  • platelet demarcation membrane
    Ç÷¼ÒÆÇ±¸È¹¸·
  • platelet sequestration
    Ç÷¼ÒÆÇ°Ý¸®
  • platelet-specific antigen
    Ç÷¼ÒÆÇƯÀÌÇ׿ø
  • random donor platelet
    ¹«ÀÛÀ§ÇåÇ÷ÀÚÇ÷¼ÒÆÇ
  • single donor platelet
    ÀÏÀÎÇåÇ÷ÀÚÇ÷¼ÒÆÇ, ÀÏÀΰøÇ÷ÀÚÇ÷¼ÒÆÇ
  • low back pain
    Ç㸮ÅëÁõ, ¿äÅë
  • low birth weight infant
    ÀúüÁßÃâ»ý¾Æ
  • low cervical cesarean section
    ¾Æ·¡ÀڱøñÁ¦¿ÕÀý°³(¼ú), ÇϺÎÀڱðæºÎÁ¦¿ÕÀý°³(¼ú)
  • low density lipoprotein
    Àú¹ÐµµÁöÁú´Ü¹éÁú
  • low dose rate
    Àú¼±·®·ü
  • low dose rate irradiation
    Àú¼±·®·üÁ¶»ç
  • low echo area
    ³·Àº¸Þ¾Æ¸®¿µ¿ª, Àú¿¡ÄÚ¿µ¿ª
  • low fever
    ¹Ì¿­
  • low field magnetic resonance scanner
    ÀúÀÚÀåÀÚ±â°ø¸í½ºÄ³³Ê
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • factor
    ÀÎÀÚ, ¿äÀÎ, °è¼ö
  • activation factor
    Ȱ¼ºÀÎÀÚ
  • antiplatelet factor
    Ç×Ç÷¼ÒÆÇÀÎÀÚ
  • coagulation V factor
    Á¦5Ç÷¾×ÀÀ°íÀÎÀÚ
  • exclusion of confounding factor
    ±³¶õº¯¼ö¹èÁ¦
  • growth factor
    ¼ºÀåÀÎÀÚ
  • intrinsic factor
    ³»ÀÎÀÎÀÚ, ³»ÀÎÀÚ
  • nerve growth factor
    ½Å°æ¼ºÀåÀÎÀÚ
  • precipitation factor
    ÃËÁø¿äÀÎ
  • predisposing factor
    ¼±Çà¿äÀÎ
  • prognostic factor
    ¿¹ÈÄÀÎÀÚ
  • psychological factor
    ½É¸®¿ä¼Ò
  • relaxing factor
    ÀÌ¿ÏÀÎÀÚ
  • resistance factor
    ³»¼ºÀÎÀÚ, °ßµõÀÎÀÚ
  • rheumatoid factor
    ·ù¸¶Æ¼½ºÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • mean platelet volume
    Æò±ÕÇ÷¼ÒÆÇ¿ëÀû
  • platelet demarcation membrane
    Ç÷¼ÒÆÇ±¸È¹¸·
  • platelet
    Ç÷¼ÒÆÇ
  • platelet refractoriness
    Ç÷¼ÒÆÇºÒÀÀÈ­
  • platelet sequestration
    Ç÷¼ÒÆÇ°Ý¸®
  • platelet immunologic refractory state
    Ç÷¼ÒÆÇ¸é¿ªºÒÀÀ»óÅÂ
  • random donor platelet
    ´ÙÀÎÇåÇ÷Ç÷¼ÒÆÇ
  • single donor platelet
    ÀÏÀΰøÇ÷Ç÷¼ÒÆÇ, ÀÏÀÎÇåÇ÷Ç÷¼ÒÆÇ
  • low echo area
    ³·Àº¸Þ¾Æ¸®¿µ¿ª, Àú¿¡ÄÚ¿µ¿ª
  • low vision aid
    Àú½Ã·Âº¸Á¶±â
  • low pressure chamber
    Àú¾Ð½Ç
  • low forceps delivery
    ÀúÀ§Áý°ÔºÐ¸¸¼ú
  • low frequency deafness
    ÀúÁ֯ij­Ã», ÀúÁÖÆÄ±Í¸ÔÀ½
  • low residue diet
    ÀúÀÜ·ù½ÄÀÌ
  • low set ear
    óÁø±Í
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • platelet-derived growth factor(pdgf)
    ÆÇ-À¯µµ¼ºÀåÀÎÀÚ(úìá³÷ù-ë¯Óôà÷íþì×í­)
  • affinity
    ģȭ¼º
  • affinity
    ģȭ¼º(öÑûúàõ), ģȭ·Â(öÑûúæ³)
  • affinity
    ģȭ¼º(öÑûúàõ), ģȭ·Â(öÑûúÕô), °áÇÕ¼º.
  • affinity
    ģȭ·Â, ģȭ¼º
  • affinity chromatography
    ģȭ(öÑûú) Å©·Î¸¶Åä±×¶óÇÇ.
  • affinity chromatography
    ģȭ¼º Å©·Î¸¶Åä±×·¡ÇÇ
  • affinity coefficient
    ģȭ°è¼ö(öÑûúÌõâ¦)
  • affinity constant
    ģȭ»ó¼ö(öÑûúßÈâ¦)
  • altered oxygen affinity
    »ê¼Òģȭ¼º º¯¼º
  • F factor (fertility factor)
    FÀÎÀÚ, ¼öÅÂÀÎÀÚ
  • Grey platelet syndrome
    ±×·¹ÀÌÇ÷¼ÒÆÇÁõÈıº
  • MPV => mean platelet volume
    Æò±ÕÇ÷¼ÒÆÇ¿ëÀû
  • granulocyte-platelet-lymphocyte antigens
    °ú¸³±¸Ç÷¼ÒÆÇ¸²ÇÁ±¸Ç׿ø
  • hemorrhagic diathesis,defective platelet function
    Ç÷¼ÒÆÇ±â´É°á¼Õ(úìá³÷ùѦÒöÌÀáß)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • affinity chromatography
    ģȭ(öÑûú) Å©·Î¸¶Åä±×¶óÇÇ.
  • affinity chromatography
    ģȭ¼º Å©·Î¸¶Åä±×·¡ÇÇ
  • affinity coefficient
    ģȭ°è¼ö(öÑûúÌõâ¦)
  • affinity constant
    ģȭ»ó¼ö(öÑûúßÈâ¦)
  • altered oxygen affinity
    »ê¼Òģȭ¼º º¯¼º
  • binding affinity
    °áÇÕģȭ¼º(Ì¿ùêöÑûúàõ)
  • chemical affinity
    È­ÇÐģȭ·Â(¡­öÑûúæ³), È­ÇÐÀû ģȭ¼º.
  • electron affinity
    ÀüÀÚģȭ·Â(¡­öÑûúæ³).
  • intrinsic affinity
    º»Å¼º ģȭ·Â, ³»À缺 ģȭ·Â
  • oxygen affinity
    »ê¼Òģȭ¼º(ß«áÈöÑûúàõ).
  • oxygen affinity abnormality
    »ê¼Òģȭ¼º( öÑûúàõ) ÀÌ»ó
  • vital affinity
    ¿µ¾çģȭ¼º(ç½å×öÑûùàõ).
  • col factor(»ýÈ­) cÀÌ ÀÎÀÚ colicin factor
    Äݸ®½ÅÀÎÀÚ.
  • lupus erythematosus factor = LE factor
    È«¹Ý¼º ·çǪ½ºÀÎÀÚ(ûõÚèàõ¡­ì×í­)
  • time, dose and fractionation factor, TDF factor
    ½Ã°£¼±·®ºÐÇÒÀÎÀÚ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cell affinity
    ¼¼Æ÷ģȭ(á¬øàöÑûú)
  • electron affinity
    "ÀüÀÚ Ä£È­¼º(ï³í­öÑûúàõ)(µµ,Óø)"
  • filter affinity transfer
    °Å¸£°Ô ģȭÀüÀÌ(öÑûúï®ì¹)
  • magnetic affinity chromatography
    ÀÚ±âģȭ(í¸ÐïöÑûú) Å©·Î¸¶Åä±×·¡ÇÇ
  • proton affinity
    ¾ç¼ºÀÚ Ä£È­µµ(öÑûúÓø)
  • low-angle x-ray diffraction
    ¼Ò°¢(á³ÊÇ) X-¼±È¸Àý(àÊüÞï¹)
  • low background counter
    ³·Àº¹ÙÅÁ °è¼ö±â(ͪâ¦Ðï)
  • low-copy number
    Àú(î¸)Ä«ÇǼö(â¦)
  • low-density fraction
    Àú¹ÐµµºÐȹ(î¸ÚËÓøÝÂüñ)
  • low-density lipoprotein
    Àú¹Ðµµ Áö´Ü¹éÁú(î¸ÚËÓøò·Ó±ÛÜòõ)
  • low-energy compound
    Àú(î¸)¿¡³ÊÁöÈ­ÇÕ¹°(ûùùêÚª)
  • low-energy electron diffraction
    Àú(î¸)¿¡³ÊÁö ÀüÀÚȸÀý(ï³í­üÞï¹)
  • low-energy ion scattering
    Àú(î¸)¿¡³ÊÁö À̿ºлê(ÝÂߤ)
  • low-energy phophate acceptor
    Àú(î¸)¿¡³ÊÁö Àλê¼ö³³Ã¼(×òß«áôÒ¡ô÷)
  • low-frequency transduction
    Àúºóµµ ÇüÁúµµÀÔ(î¸ÞºÓøû¡òõÓôìý)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • low intensity void in proton flow
    ¾ç¼ºÀÚÈ帧ÀÇ Àú°­µµ¼Ò½Ç
  • low pass filter
    ÀúÅë°ú¿©°ú±â
  • low signal
    Àú½ÅÈ£
  • low signal intensity
    Àú½ÅÈ£°­µµ
  • ultra low field MR scanner
    ÃÊÀúÀÚÀåÀÚ±â°ø¸í½ºÄ³³Ê
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PA panic attack; pantothenic acid; paralysis agitans; paranoia; passive aggressive; pathology; patient'...
EF ectopic focus; edema factor; ejection fraction; elastic fibril; electric field; elongation factor; e...
LPF leukocytosis-promoting factor; leukopenia factor; lipopolysaccharide factor; localized plaque format...
HALC high affinity-low capacity
LAHC low affinity-high capacity
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
AC Affinity chromatography
3H High affinity
HAChT High affinity choline transport
HACU High affinity choline uptake
HA High-affinity
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • electron affinity
    ÀüÀÚ Ä£È­·Â
    ¿øÀÚ°¡ ÀüÀÚ 1°³¿Í °áÇÕÇÒ ¶§¿¡ ¹æÃâÇÏ´Â ¿¡³ÊÁö.
  • high-affinity agonist
    °íģȭ¼º ÀÛ¿ë ¹°Áú
  • morbid affinity
    Áúº´ ģȭ¼º
  • oxygen affinity
    »ê¼Ò ģȭ¼º
  • vital affinity
    ¿µ¾ç ģȭ¼º
  • IGF-I : insulin like growth factor-IÀÇ ¾àÀÚ. ¼ºÀåÆÇÀÎ epiphyseal plate¿¡ ¿¬°ñ »ý¼ºÀ» Áõ°¡½ÃÄÑ »ÀÀÇ ¼ºÀåÀ» ÃËÁøÇÑ´Ù.

    IGF-II : insulin like growth factor-IIÀÇ ¾àÀÚ. ¸¹Àº Àå±â¿Í Á¶Á÷¿¡ ÀÛ¿ëÇÏ¿© ´Ü¹é ÇÕ¼º°ú DNA, RNAÀÇ ÇÕ¼ºÀ» Áõ°¡½ÃÄÑ ¼¼Æ÷ÀÇ ¼ö¿Í ¾çÀ» Áõ°¡

    Àν¶¸°¾ç ¼ºÀå ÀÎÀÚ °áÇÕ ´Ü¹éÁú
    insulinelike growth factor binding
  • single-factor versus multiple-factor analysis
    ´ÜÀÏ ¿ä¼Ò ºÐ¼® ´ë º¹ÇÕ ¿ä¼Ò ºÐ¼®
  • Castellani-Low symptom
    Ä«½ºÅÚ¶ó´Ï-·Î¿ì Áõ»ó
    ¼ö¸éº´ ȯÀÚ¿¡°Ô¼­ º¼ ¼ö ÀÖ´Â ¼³ ÁøÀü.
  • low
    ³·Àº, Àú
  • low birth weight
    ÀúüÁß Ãâ»ý
  • low carat gold alloy
    ÀúÄ«¶óÆ® ±Ý ÇÕ±Ý
    16Ä«¶óÆ® ÀÌÇÏÀÇ ±Ý ÇÕ±Ý. ³³Âø ÇÕ±ÝÀ» ¸»ÇÑ´Ù.
  • low copper amalgam
    Àú µ¿ ¾Æ¸»°¨
  • low frequency
    ÀúÁÖÆÄ
    Á֯ļö°¡ ³·Àº ÆÄ. Áï, ÀüÀÚ±âÆÄÀÇ Á֯ļö¿¡ ÀÇÇÑ ºÐ·ù·Î¼­, º¸Åë 10 kHz ÀÌÇϸ¦ ¸»ÇÑ´Ù. ¿Àµð¿À
  • low frequency therapeutic apparatus
    ÀúÁÖÆÄ Ä¡·á±â
  • low fusing porcelain
    Àú¿Â ¿ëÀ¶ µµÀç
    Ä¡°ú¿ë µµÀçÀÇ Á¾·ùÀε¥ 1600¡Æ¡­2000¢µ¿¡¼­ 󸮵Ǵ µµÀçÀÌ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
affinity tag <biochemistry, molecular biology> A short amino acid sequence, usually engineered onto the N- or C-terminus of a protein, to make its purification easier.
(14 Nov 1997)
antibody affinity A measure of the binding strength between antibody and a simple hapten or antigen determinant. It depends on the closeness of stereochemical fit between antibody combining sites and antigen determinants, on the size of the area of contact between them, and on the distribution of charged and hydrophobic groups. It includes the concept of "avidity," which refers to the strength of the antigen-antibody bond after formation of reversible complexes.
(12 Dec 1998)
residual affinity Secondary forces that enable apparently saturated atoms, ions, or molecules to attract other atoms or groups, causing such phenomena as complex formation, hydration, adsorption, etc.
(05 Mar 2000)
chromatography, affinity A chromatographic technique that utilises the ability of biological molecules to bind to certain ligands specifically and reversibly. It is used in protein biochemistry.
(12 Dec 1998)
oxygen affinity anoxia Anoxia due to inability of haemoglobin to release oxygen.
(05 Mar 2000)
oxygen affinity hypoxia Hypoxia due to reduced ability of haemoglobin to release oxygen.
(05 Mar 2000)
acquired platelet function defect <haematology> Platelet function can be affected by a number of different disease processes including polycythaemia vera, leukaemia, myelofibrosis, renal failure, multiple myeloma and some medications (for example penicillins, salicylates, phenothiazines).
Disturbed blood clotting can be manifested by: easy bruising, bleeding gums, nosebleeds, abnormal vaginal bleeding, rectal bleeding, skin rash, vomiting blood, coughing up blood or blood in the urine. A measure of bleeding time and coagulation profile will be part of the evaluation.
(29 Dec 1997)
antigens, human platelet Human alloantigens expressed only on platelets, specifically on platelet membrane glycoproteins. These platelet-specific antigens are immunogenic and can result in pathological reactions to transfusion therapy.
(12 Dec 1998)
anti-platelet agents Medications that, like aspirin, reduce the tendency of platelets in the blood to clump and clot.
(12 Dec 1998)
medication, anti-platelet Platelet-blocking drugs. Drugs that, like aspirin, reduce the tendency of platelets in the blood to clump and clot.
(12 Dec 1998)
platelet <haematology> A discoid cell (3m diameter) found in large numbers in blood, important for blood coagulation and for haemostasis by repairing breaches (small breaks) in the walls of blood vessels.
Platelet _ granules contain lysosomal enzymes, dense granules contain ADP (a potent platelet aggregating factor) and serotonin (a vasoactive amine). They also release platelet-derived growth factor which presumably contributes to later repair processes by stimulating fibroblast proliferation.
Synonym: thrombocytes.
(09 Oct 1997)
platelet activation A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable haemostatic plug.
(12 Dec 1998)
platelet actomyosin The contractile protein of platelets, responsible for clot retraction, platelet aggregation, and release of ADP and other biologic amines essential to platelet function.
Synonym: thrombosthenin.
(05 Mar 2000)
platelet adhesiveness The process whereby platelets adhere to something other than platelets, e.g., collagen, basement membranes, microfibrils, or other "foreign" surfaces.
(12 Dec 1998)
platelet aggregation The attachment of platelets to one another. This clumping together can be induced by a number of agents (e.g., thrombin, collagen) and is part of the mechanism leading to the formation of a thrombus.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • intrinsic factor
    (»ýÈ­)³»À缺ÀÎÀÚ
  • nerve growth factor
    (»ý¸®)½Å°æ ¼ºÀåÀÎÀÚ(Áö°¢(±³°¨)½Å°æ¼¼Æ÷ÀÇ ¼ºÀåÀ» ÀÚ±ØÇÏ´Â ´Ü¹éÁú)
  • noise factor(figure)
    (ÁõÆø±â¿¡¼­ÀÇ)ÀâÀ½Áö¼ö
  • pp factor
    Ç× Æç¶ó±×¶ó ÀÎÀÚ(Æç¶ó±×¶ó ¿¹¹æ¿¡ ¾²´Â ´ÏÄÚÆ¾»ê,´ÏÄÚÆ¾»ê¸¶À̵å)
  • prime factor
    ¼ÒÀμö
  • releasing factor
    È£¸£¸ó ¹æÃâÀÎÀÚ
  • rheumatoid factor
    ·ù¸ÓƼÁòÀÎÀÚ(¸¸¼º °üÀý ·ù¸ÓƼÁò ȯÀÚÀÇ ÀÚ±â Ç×ü)
  • low
    ³·Àº,³·°Ô,õÇϰÔ,(¼Ò°¡)¿ï´Ù
  • low-minded
    ºñ¿­ÇÑ
  • Low Church
    Àú±³È¸ÆÄ(¿µ±¹ ±¹±³ÆÄÁß,±³È¸ÀÇ ±³¸®,ÀǽĿ¡ ÁßÁ¡À» µÎÁö ¾Ê´Â ÇÑ ÆÄ)
  • Low Churchman
    Àú±³È¸ÆÄÀÇ »ç¶÷
  • Low Countries
    Áö±ÝÀÇ BeneluxÀÇ ÃÑĪ
  • Low Mass
    Æò¹Ì»ç
  • Low Sunday
    ºÎȰÀý ´ÙÀ½ÀÇ ÀÏ¿äÀÏ
  • Middle Low German
    Áß¼¼(Áß±â) ÀúÁö µ¶ÀϾî(12-15¼¼±â)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á